FDA Approves Once-Weekly Semaglutide for T2DM

December 5, 2017. The US Food and Drug Administration (FDA) has approved the once-weekly injectable glucagon-like peptide-1 receptor agonist semaglutide (0.5 and 1.0 mg doses) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. This approval was predicated on data from 8 major clinical trials, comprising more than 8,000 patients, and including a FDA-mandated cardiovascular outcomes trial. Follow this link to read the manufacturer’s press release.